ResMed Inc. — 8.3/10
ResMed Inc. is the global leader in sleep apnea and respiratory care, selling PAP flow-generator devices, masks and accessories, and an out-of-hospital residential-care SaaS layer (Brightree, MatrixCare). The company holds ~48% global (and above 55% US) share of the sleep-apnea device market — a position it cemented when Philips exited the US device market on its 2021 Respironics recall — plus the #1 mask franchise, which throws off a sticky razor/blade resupply annuity.
The setup is unusually clean: a quality-bar-clearing market leader that clears all three pre-score gates (oligopoly, growing FCF, management track record) with no cap applied. Revenue is compounding in a stable-to-accelerating ~9-11% band, gross margin is expanding materially toward a stated 2030 target, and free cash flow is growing on a net-cash balance sheet. The one genuine debate — whether GLP-1 weight-loss drugs are a substitution threat — is where management is loudly, specifically, and data-backed on the opposite side of the street (management shows GLP-1 patients start and stay on CPAP at higher rates), an NVDA-shaped divergence the market has not underwritten and which shows up in a discounted ~17.9x forward P/E.
| CEO | Mick Farrell (~13 yrs) | Revenue Growth | Stable-to-accel (+10.8% latest Q) |
| Secular Tailwinds | Undersupplied OSA TAM / GLP-1 funnel | FCF Trajectory | Growing, net-cash balance sheet |
| Market Position | #1 device (~48% global) & #1 mask | FYE | June 30 |
| Quality Gate | FULL PASS (0 NOs) | Margin Trend | Expanding |
| Dimension | Score | Weight | Weighted |
|---|---|---|---|
| Financial Trends | 9 | 25% | 2.25 |
| Thematic Exposure | 8 | 35% | 2.80 |
| Management Quality | 9 | 20% | 1.80 |
| Investor Sentiment (Inverted) | 8 | 5% | 0.40 |
| Concerns / Risks | 7 | 15% | 1.05 |
| Composite | 100% | 8.3 |
A quality-bar-clearing market leader that scores 8.3/10 with no gate cap. ResMed is a sleep-apnea device oligopolist (~48% global / above-55% US share) with 9/10 financials — stable-to-accelerating revenue (+10.8% latest quarter), gross margin expanding to 62.2%, growing FCF, and a declining share count. It pairs top-decile financials (9/10) with a durable oligopolistic thematic position (8/10), a top-decile 13-year management team that has delivered 100% of guidance (9/10), a clean inverted-sentiment divergence (8/10), and a benign, below-peer-valuation risk profile (7/10).
Quality gate: FULL PASS (0 NOs). Oligopoly YES. Growing FCF YES. Management track record YES. All three gates clear, so no cap applies — the composite reflects the full weighted math.
ResMed's financial profile is genuinely top-decile: stable-to-accelerating revenue, materially expanding gross margins (GAAP GM up ~290bps YoY to 62.2%), growing free cash flow, and a net-cash balance sheet funding a roughly doubled buyback. Management has hit 100% of measurable forward commitments and runs a consistent beat-and-raise cadence, lifting gross-margin guidance to 61-63% and committing to double-digit-bps GM improvement every year through 2030.
The central debate is GLP-1. The street prices weight-loss drugs as a substitution threat to CPAP; management brings a quantified, longitudinal dataset (claims data on 1.95M patients showing GLP-1 + CPAP patients start therapy 10-11% more and resupply 6.2% more at three years) arguing the opposite — that GLP-1s expand the diagnosed funnel. This is the NVDA-shaped configuration: a credible team repeating a specific, falsifiable bullish claim the market will not underwrite, reflected in a discounted ~17.9x forward P/E versus a ~20-22x MedTech peer band.
The main bear arguments — Philips' eventual US device re-entry and a maturing ex-US/RCS growth profile — are real but manageable, and the reimbursement/tariff backdrop is improving (CPAP excluded from CMS competitive bidding, decades of Nairobi-Protocol tariff relief, US manufacturing build-out). The result is an asymmetric, favorable set-up with limited downside.